ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer

Affiliations

¹ Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
² Department of Clinical Laboratory, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
³ Department of General Surgery, The First People's Hospital of Xiangtan, Xiangtan, China.
⁴ Department of Breast and Thyroid Surgery, The First People's Hospital of Chenzhou, Chenzhou, China.
⁵ Department of Breast Surgery, The Affiliated Zhuzhou Hospital of Xiangya School of Medicine, Zhuzhou, China.
⁶ Department of Breast and Thyroid Surgery, The Third People's Hospital of Chenzhou, Chenzhou, China.
⁷ Department of Breast and Thyroid Surgery, The First People's Hospital of Huaihua, Huaihua, China.
⁸ Changsha Medical University, Changsha, China.
⁹ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
¹⁰ Department of Breast Surgery, Multidisciplinary Breast Cancer Center, Xiangya Hospital, Central South University, Changsha, China.
¹¹ Department of Breast Surgery, General Surgery, Clinical Research Center for Breast Cancer in Hunan Province, National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Xiangya Hospital, Central South University, Changsha, China. zhixiao@csu.edu.cn.

Jian Pang et al. Ann Surg Oncol. 2025 Mar.

. 2025 Mar;32(3):2110-2111.

doi: 10.1245/s10434-024-16664-0. Epub 2024 Dec 10.

¹ Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
² Department of Clinical Laboratory, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
³ Department of General Surgery, The First People's Hospital of Xiangtan, Xiangtan, China.
⁴ Department of Breast and Thyroid Surgery, The First People's Hospital of Chenzhou, Chenzhou, China.
⁵ Department of Breast Surgery, The Affiliated Zhuzhou Hospital of Xiangya School of Medicine, Zhuzhou, China.
⁶ Department of Breast and Thyroid Surgery, The Third People's Hospital of Chenzhou, Chenzhou, China.
⁷ Department of Breast and Thyroid Surgery, The First People's Hospital of Huaihua, Huaihua, China.
⁸ Changsha Medical University, Changsha, China.
⁹ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
¹⁰ Department of Breast Surgery, Multidisciplinary Breast Cancer Center, Xiangya Hospital, Central South University, Changsha, China.
¹¹ Department of Breast Surgery, General Surgery, Clinical Research Center for Breast Cancer in Hunan Province, National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Xiangya Hospital, Central South University, Changsha, China. zhixiao@csu.edu.cn.

No abstract available

Conflict of interest statement

Disclosure: The authors declare no competing financial or nonfinancial interests.

1. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19. https://doi.org/10.1056/NEJMoa1113216 . - DOI - PubMed
1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92. https://doi.org/10.1056/nejm200103153441101 . - DOI - PubMed
1. Pang J, Ding N, Liu X, et al. Prognostic value of the baseline systemic immune-inflammation index in HER2-positive metastatic breast cancer: exploratory analysis of two prospective trials. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-16454-8 . - DOI - PubMed